Precise Biopharma Private Limited - Due diligence report

A 360° intelligence report on Precise Biopharma Private Limited: trust score, financial health, credit view, compliance, directors, growth a…

2005-04-06 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
Connect MCP
PB Precise Biopharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Precise Biopharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
85/100
Trust Score
Low Risk

Precise Biopharma Private Limited is assessed as Low Risk with a Trust Score of 85/100. Precise Biopharma Private Limited is an active private limited indian non-government company incorporated in 2005, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 05 Aug 2026 from the latest processed filings. Precise Biopharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
85/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
74/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
65/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
60/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 65/100 Moderate
  • Profitable - internal accruals available.

Charges position: 7 open (56.92 cr) · 2 satisfied (4.75 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Axis Bank Limited2 48.0 cr
Others4 48.0 cr
Ing Vysya Bank Limited1 48.0 cr
Hdfc Bank Limited2 48.0 cr
Compliance Score: 74/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 2 court forum(s).
  • 7 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
MEHUL PRAVIN SHAH 01234567 Director 01/04/2018 6 yrs Approved
SUNIL SADANAND SUKHATHANKAR 01234567 Director 01/04/2018 6 yrs Approved
Rachana Mehul Shah 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2025 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 0 transfer(s)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 60 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +38% over 4 year(s).
Operating for 21+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
7 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence82/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment72/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 7 open charge(s) of 56.92 cr already registered.
  • Compliance record supports lending.
Investor view73/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
25 Sep 2025
Charge created
Others - 1.27 cr
20 Aug 2025
Director appointed
Rachana Mehul Shah (Additional Director)
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
29 Feb 2024
Charge created
Others - 20.00 Lakh
05 Oct 2023
Charge created
Others - 9.00 cr
30 Sep 2022
Director ceased
SUNIL SADANAND SUKHATHANKAR
31 Mar 2022
Charge created
Axis Bank Limited - 5.00 cr
20 Aug 2021
Director appointed
SUNIL SADANAND SUKHATHANKAR (Director)
Director ceased
PRANAY PRAVIN SHAH
Director ceased
PRAVIN VRAJLAL SHAH
28 Jun 2021
Charge created
Hdfc Bank Limited - 8.02 Lakh
31 Mar 2021
Charge created
Hdfc Bank Limited - 28.87 Lakh
15 Oct 2020
Securities allotted
1625000 Equity Shares - 1.63 cr raised
17 Aug 2020
Charge satisfied
Others
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - leverage worth monitoring.
Net worth is positive.
3 active director(s) / partner(s); board looks stable and experienced.
7 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
M B Sugars And Pharmaceuticals Private Limited U15420MH1996PTC096832 Nashik, Maharashtra, India
Srinivasa Cystine Private Ltd U24110TG1983PTC003897 Ap, Telangana, India
Aimcopesticides L24210MH1987PLC044362 Lote Parshuram, Maharashtra, India
Maharashtra Pesticide Limited U24219MH1999PLC118304 Navi Mumbai, Maharashtra, India
Orient Ethanol Industries Private Limited U24290DL2022PTC400747 Delhi, Delhi, India
Mayuri Kumkum Limited U24290MH2021PLC369428 Thane, Maharashtra, India
Crop Life Science L24124GJ2006PLC048297 Vadodara, Gujarat, India
Panila Chem Limited U24303GJ2017PLC096453 Bhavnagar, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Precise Biopharma Private Limited before audits and certifications: compliance score 74/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Precise Biopharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 65/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 60/100, margin trends, ownership structure and peer set for Precise Biopharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 85/100, distress signals and MSME payment-delay disclosures - know whether Precise Biopharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Precise Biopharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Precise Biopharma Private Limited an active company?

Precise Biopharma Private Limited has MCA status “Active” with a compliance score of 74/100 (Moderate).

Is Precise Biopharma Private Limited financially healthy?

Precise Biopharma Private Limited has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Precise Biopharma Private Limited?

Its overall Trust Score is 85/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Precise Biopharma Private Limited?

See the directors and ownership sections above for board and shareholding detail. 3 active director(s) are on record.

Does Precise Biopharma Private Limited have loans or charges against its assets?

7 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.

Is Precise Biopharma Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 74/100 (Moderate).

Is it risky to lend to Precise Biopharma Private Limited?

Its Credit Risk Score is 65/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.